BrainsWay Ltd. — Cyborg Score 7/10

Strong
Medical Devices - Neurostimulation/Psychiatry

Strategic Profile

Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Israel Ministry of Defense's Rehabilitation Department has granted approval for the reimbursement of Deep TMS therapy for qualifying patients with post-traumatic stress disorder (PTSD) at Israeli public hospitals, expanding the company's addressable market and establishing strong domestic reimbursement pathways.

Cyborg Score Rationale

As of June 2025, BrainsWay has trailing 12-month revenue of $46.1M, demonstrating commercial traction. The company benefits from multiple FDA clearances, expanding insurance coverage, and growing international reimbursement, though the modest market cap of ~$281M reflects competitive pressures in the neurostimulation market.

Top Insights

  • BrainsWay increased its presence in Israel with 11 recent system installations driven by a 45% increase in reimbursement rates
  • The company's flagship technology is based on deep transcranial magnetic stimulation, aimed at helping smokers quit (FDA cleared since August 2020)
  • BrainsWay holds CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions including post-traumatic stress disorder and Alzheimer's disease
  • Recent Valor Equity Partners partnership signals institutional validation and growth capital for market expansion

Named Competitors

  • TMS Systems — Transcranial magnetic stimulation systems for depression treatment
  • Deep Brain Stimulation — Invasive neuromodulation alternatives
  • Esketamine — Pharmaceutical treatment for treatment-resistant depression

Recent Developments

  • (January 2026) FDA approval of Neurolief's Proliv Rx neuromodulation system for major depressive disorder
  • (December 2025) Optum expanded Deep TMS coverage for teens, broadening addressable patient population
  • (September 2024) Israel Ministry of Defense granted PTSD reimbursement approval at Israeli hospitals

Open the full interactive BrainsWay Ltd. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →